Current EU regulations allow cancer drug companies to opt out of trials on children meaning less drugs are available for children suffering from cancer. 

The reason drug companies are able to avoid testing drugs on children is because certain cancers rarely affect children and as the trials can be expensive, the drug companies want the trials to be worth while.

However, Cancer research UK want the opt out options tightened because cancer medicines are evolving and can often be used for many different types of cancers. 

Children are the future so it's important for children with cancer to get the best possible treatment and the latest medicines available.